Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.

Journal of Cancer Research and Clinical Oncology
Christos MarkopoulosHelen Gogas

Abstract

We investigated whether age at anastrozole (A) initiation influences the effect of treatment on bone mineral density (BMD). We conducted a post hoc analysis of the dataset of Arimidex Bone Mass Index Oral Bisphosphonates prospective trial, studying the effect of risedronate (R) on BMD of postmenopausal, early breast cancer patients receiving A. Patients were stratified into those with normal BMD or mild osteopenia (T > -2) receiving A-only and patients with mild or severe osteopenia (T ≤ -2) or osteoporosis (T < -2.5) receiving A and per os R (A + R). Depending on age on treatment initiation, patients were grouped into two age cohorts, above and below 65 years. BMD change in lumbar spine (LS) and hip (HP) was evaluated at 12 months. An analysis of patients with normal BMD at baseline was additionally performed. Among patients receiving A-only, women ≤65 years were more likely to have a decrease in LS-BMD than older (p = 0.034). HP-BMD decrease at 12 months was not related to age (p = 0.182). In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0.099 and p = 0.939, respectively). Among patients with normal BMD at baseline, the age effect on LS-BMD change was...Continue Reading

References

Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Dec 16, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J J BodyR D Rubens
Mar 31, 1999·British Journal of Cancer·J A KanisT Spector
Sep 4, 1999·The Netherlands Journal of Medicine·P C de Jong, G H Blijham
Feb 26, 2000·The Journal of Clinical Endocrinology and Metabolism·G A LaughlinD von Mühlen
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jürgen GeislerPer Eystein Lønning
Mar 7, 2002·Breast Cancer Research : BCR·Herbert Fleisch
May 7, 2003·The Lancet Oncology·Andrew J AshcroftGareth J Morgan
Mar 12, 2004·The New England Journal of Medicine·R Charles CoombesUNKNOWN Intergroup Exemestane Study
Dec 8, 2004·The Journal of Clinical Endocrinology and Metabolism·Ashild BjørneremGro K Rosvold Berntsen
Jun 20, 2006·Lancet·Philip Sambrook, Cyrus Cooper
Jul 28, 2006·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Richard EastellUNKNOWN ATAC Trialists' group
Nov 23, 2006·Journal of the National Comprehensive Cancer Network : JNCCN·Robert W CarlsonUNKNOWN St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael F X GnantUNKNOWN Austrian Breast and Colorectal Cancer Study Group
Aug 19, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H S Rugo
Oct 2, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M AaproB Thürlimann
Mar 12, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Diana CrivellariAron Goldhirsch
Apr 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Michael DixonMitch Dowsett
Aug 16, 2008·The Lancet Oncology·Ivana SestakUNKNOWN ATAC Trialists' Group
Sep 4, 2008·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·Z ChenR T Chlebowski
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James E LesterRobert E Coleman
Jan 27, 2009·Clinical Oncology : a Journal of the Royal College of Radiologists·J Yarnold
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Lorna GibsonJudith Bliss
Jan 13, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine Van PoznakRichard Eastell
Apr 30, 2010·Critical Reviews in Oncology/hematology·Michael Gnant, Holger Eidtmann
Apr 30, 2010·Human Reproduction Update·UNKNOWN ESHRE Capri Workshop Group
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold J BursteinUNKNOWN American Society of Clinical Oncology
Oct 14, 2010·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Alexandra PapaioannouUNKNOWN Scientific Advisory Council of Osteoporosis Canada
Dec 21, 2010·Calcified Tissue International·Diane E PowellMichael W J Davie

❮ Previous
Next ❯

Citations

Mar 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B BouvardE Legrand
Jul 26, 2015·Current Osteoporosis Reports·Gregory A ClinesCatherine Van Poznak
Mar 21, 2015·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·S L GreenspanS Perera
Apr 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B BouvardE Legrand

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray

Clinical Trials Mentioned

NCT00809484

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.